Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Fred Levine who wrote (924)	5/1/1998 8:42:00 AM
From: madman	Respond to of 1605

FRED,Thanks for the input.

To: Fred Levine who wrote (924)	5/1/1998 9:26:00 AM
From: Jack Ucci	Respond to of 1605

Still holding on to my shares. With the price so low I cannot do much else. The posts giving 44 and now 45 centers were one month apart. I would like a faster rate of increase, but a steady rate is welcomed. It would seem that their strategy will succeed eventually. The only question is WHEN is eventually!!!

To: Fred Levine who wrote (924)	5/8/1998 2:08:00 PM
From: Jack Ucci	Read Replies (1) \| Respond to of 1605

News this morning may explain the recent increase in volume. The following announcement has not been greeted with the response it may get upon further reflection. VASO must have plans in place to make good use of this financing: Vasomedical Announces $3.5 Million Financing; Proceeds to Expand Marketing Programs Business Wire - May 08, 1998 10:38 %VASOMEDICAL VASO %NEW-YORK %MEDICINE V%BW P%BW _ WESTBURY, N.Y.--(BW HealthWire)--May 8, 1998--Vasomedical Inc. (NASDAQ:VASO), announced that it has received $3.5 million to expand its marketing programs to increase awareness of the benefits of EECP(R) therapy among physicians, patients and insurers. This second tranche of financing from the same institutional investor from which the company received funds last year demonstrates the investor's confidence in the EECP(R) technology, its broad usefulness in the treatment of cardiovascular diseases and the company's long-term economic outlook. Anthony Viscusi, president and CEO of Vasomedical, stated that "the increasing acceptance of the EECP(R) procedure as a scientifically validated option in the treatment of coronary artery disease and the increasing insurance reimbursement successes achieved by most current treatment centers around the country indicate that the market is ready to respond to a stepped-up marketing effort. The company has already doubled its sales force and the new funding will enable us to undertake specific marketing initiatives, including customer support programs to further increase patient recruitment and insurance reimbursement, as well as seeding programs in capitated HMO settings where EECP(R), as a noninvasive, outpatient therapy, has the potential to create considerable economic benefits because of the elimination of hospital days and the avoidance of other costs associated with invasive procedures." The financing, consummated through the issuance of 5% Series C Convertible Preferred Stock, was facilitated by Wharton Capital, a New York-based financial consulting firm.